OYE THEREPEUTICS

Lobbying Spend

—

Filings

Firms Hired

Active Period

2021–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	3	1
2025	—	4	1
2024	—	4	1
2023	—	4	1
2022	—	4	1
2021	—	5	1

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
BELL & LINDSAY, INC. (FORMERLY WHITE HOUSE CONSULTING INC.)	—	24

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
Defense, Dept of (DOD)	22
HOUSE OF REPRESENTATIVES	22
Office of Management & Budget (OMB)	22
Office of Natl Drug Control Policy (NDCP)	22
Office of Science & Technology Policy (OSTP)	22
SENATE	22
Executive Office of the President (EOP)	20
Food & Drug Administration (FDA)	17
Health & Human Services, Dept of (HHS)	8

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	24

OYE THEREPEUTICS — Lobbying Disclosure | Poliscope